West Pharmaceutical Services, Inc. — Cyborg Score 7/10
Strong
Pharmaceutical Packaging & Drug Delivery Systems
Strategic Profile
The company operates in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). Q1 2026 delivered 21% revenue growth and 47% higher adjusted EPS, driven by strong HVP component and biologics demand, with full-year guidance raised for both revenue and EPS. The company benefits from tailwinds in GLP-1 receptor agonists and large-molecule biologics demand.
Cyborg Score Rationale
With a market capitalization of $21.4B (as of May 2026), West demonstrates robust scale and financial strength. However, the company faces skepticism despite a 14.2% free-cash-flow margin due to modest sales growth and declining operating margins, with analysts highlighting valuation risks at a 37.8x forward P/E. Strong recent performance partially offsets valuation concerns.
Top Insights
(April 2026) Q1 2026 beat expectations with 21% revenue growth and 47% adjusted EPS growth, benefiting from high-value product (HVP) demand and biologics surge
Strong beneficiary of GLP-1 receptor agonist and large-molecule biologics adoption, with approximately 55% revenue from international markets providing geographic diversification
Proprietary products segment drives 80% of revenue with higher margins, while contract-manufactured products offer growth diversification in surgical and diagnostic devices
Valuation concerns persist at 37.8x forward P/E despite operational execution, suggesting stock has priced in substantial growth expectations
Named Competitors
Elastomer Solutions — Pharmaceutical packaging and medical device components
Injectable Delivery Systems — Medical devices and injectable drug delivery
BD Medical — Medical technology and pharmaceutical delivery
HealthCare Technologies — Medical device and healthcare solutions
Recent Developments
(April 2026) Raised full-year revenue and EPS guidance following strong Q1 2026 performance with 21% revenue growth and 47% adjusted EPS growth
(May 2026) Stock price trading at $302.89 with $21.4B market capitalization reflecting strong market confidence
Momentum driven by proprietary high-value products (HVP) components and demand surge from injectable biologics and GLP-1 therapies
Open the full interactive West Pharmaceutical Services, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.